Earnings Call Insights: CareDx (CDNA) Q2 2026
Management View
- John Hanna (President, CEO & Director) said CareDx’s multi-year portfolio shift is “largely complete,” citing exits from “non-core businesses” and an expansion of its “solutions approach into specialty oncology and cell therapy,” while reiterating the company is targeting markets where it can “hold
Seeking Alpha’s Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
